SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit") today announced the opening of cutting-edge laboratory space in Cambridge, United Kingdom, a global centre for research and development for companies at the forefront of life science innovation. This strategic acquisition marks a pivotal milestone for Conduit, positioning the Company for portfolio expansion, enhanced development capabilities, and growth of a robust inte ...

SAN DIEGO and LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit"), a multi-asset, clinical-stage life science company delivering an efficient model for compound development, today announced CEO Dr. David Tapolczay, will be participating in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, being held February 13-14, 2024. Dr. Tapolczay is scheduled to present on Wednesday, February 14, 2024, at 8:00 am EST/13:30 GMT, and will be participating in one- ...

| --- | --- | --- | --- | --- | |--------------------------------------------------------------------------------|-------|---------------------------|-------|--------------------| | Net cash (used in) provided by: \nOperating Activities | $ | Months 2023 \n(2,922) | \n$ | 30, 2022 \n(1,386) | | Investing Activities | | 228 | | (129) | | Financing Activities | | 11,343 | | 1,515 | | Effect of exchange rate changes on cash and cash equivalents | | (5) | | - | | Net (decrease) increase in cash and cash equival ...

As of the date of this Quarterly Report on Form 10-Q, there have been no material changes from the risk factors previously disclosed in our Annual Report for the year ended December 31, 2022, except as set forth below. Risks associated with the Merger and Conduit are more fully discussed in the Form S-4 that the Company has filed, as may be amended. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not p ...

● increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; Merger Agreement In connection with the transactions contemplated by the Merger Agreement, we entered into a subscription agreement (the "Subscription Agreement") with an investor. Pursuant to the Subscription Agreement, the investor has agreed to purchase $27 million (the "Private Placement") units of our securities, with each unit consisting of (i) one share o ...

Title of each class Trading Symbol Name of each exchange on which registered FORM 10-K For the transition period from to Registrant's telephone number, including area code: 760-471-8536 None Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 1 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41245 MURPHY CANYON ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41245 MURPHY CANYON ACQUISITION CORP. | --- | --- | |---------------------------------------------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41245 MURPHY CANYON ACQUISITION CORP. | --- | --- | |--------------------------------------------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 | --- | |-----------------------------------------------| | | | Units, each consisting of one share | | Class A Common Stock and one | | Redeemable Warrant | MURFU The Nasdaq Stock Market LLC | --- | --- | --- | |-----------------------------------------------------|-------|-------------------------------------| | | | | | Class A Common Stock, par value $0.0001 | MURF | The Nasdaq Stock Market LLC | | per share | | | | --- | |------------ ...